The High Court in Pretoria has dismissed a pharmacy's appeal against a ruling that blocked its compounding of semaglutide, a medication used for diabetes and weight management. IDexis (Pty) Ltd, operating under the name Sentra Pharmacy, had sought permission to challenge the decision, but the court denied its request. The ruling was based on regulatory concerns over the safety and efficacy of compounded medications. The court emphasized that compounding without proper authorization could pose risks to patient health. The decision comes amid ongoing debates over the regulation of compounded drugs in South Africa. The pharmacy had argued that its compounding process met all necessary standards, but the court found no grounds to overturn the initial ruling. The case highlights the challenges faced by pharmacies in navigating complex regulatory frameworks.